Results for tag: "Darapladib"

Darapladib is a cardiovascular drug used to treat coronary artery disease. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, which works by reducing the activity of an enzyme that contributes to the formation of fatty deposits in the arteries. This helps to reduce the risk of heart attack and stroke. Darapladib is available in both oral and intravenous formulations. It is typically prescribed in combination with other medications, such as statins, to reduce the risk of cardiovascular events. The darapladib market is a relatively small but growing segment of the cardiovascular drug market. It is primarily driven by the increasing prevalence of coronary artery disease and the need for more effective treatments. The market is expected to benefit from the development of new formulations and the introduction of generic versions of the drug. Some of the major companies in the darapladib market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of darapladib and other cardiovascular drugs. Show Less Read more